S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
3rd Massive Dollar Upheaval Has Started (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
Sick of seeing others get rich in the stock market? Let Stock Advisor help (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
3rd Massive Dollar Upheaval Has Started (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
Sick of seeing others get rich in the stock market? Let Stock Advisor help (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
3rd Massive Dollar Upheaval Has Started (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
Sick of seeing others get rich in the stock market? Let Stock Advisor help (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
3rd Massive Dollar Upheaval Has Started (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
Sick of seeing others get rich in the stock market? Let Stock Advisor help (Ad)
NASDAQ:HCAT

Health Catalyst - HCAT Stock Forecast, Price & News

$12.83
+0.23 (+1.83%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.56
$13.12
50-Day Range
$11.35
$18.27
52-Week Range
$10.95
$57.19
Volume
1.59 million shs
Average Volume
899,873 shs
Market Capitalization
$702.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.69

Health Catalyst MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
108.0% Upside
$26.69 Price Target
Short Interest
Healthy
6.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.72
Upright™ Environmental Score
News Sentiment
-0.14mentions of Health Catalyst in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$93,877 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.80) to ($1.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

186th out of 1,112 stocks

Computer Programming, Data Processing, & Other Computer Related Industry

17th out of 68 stocks

HCAT stock logo

About Health Catalyst (NASDAQ:HCAT) Stock

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. JPMorgan Chase & Co. cut Health Catalyst from an "overweight" rating to a "neutral" rating and reduced their target price for the company from $20.00 to $16.00 in a research note on Friday, August 5th. The Goldman Sachs Group reduced their target price on Health Catalyst from $29.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday. Royal Bank of Canada reduced their price objective on Health Catalyst from $35.00 to $19.00 in a research note on Wednesday, May 11th. Citigroup reduced their price objective on Health Catalyst from $45.00 to $25.00 in a research note on Wednesday, May 11th. Finally, BTIG Research reduced their price objective on Health Catalyst from $35.00 to $25.00 in a research note on Wednesday, July 27th. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $26.69.

Health Catalyst Trading Up 1.8 %

Health Catalyst stock opened at $12.83 on Friday. The firm has a 50-day moving average of $15.12 and a 200-day moving average of $20.17. The firm has a market cap of $702.10 million, a P/E ratio of -4.38 and a beta of 1.14. Health Catalyst has a 1-year low of $10.95 and a 1-year high of $57.19.

Health Catalyst (NASDAQ:HCAT - Get Rating) last posted its earnings results on Tuesday, May 10th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.03. Health Catalyst had a negative net margin of 54.64% and a negative return on equity of 18.31%. The company had revenue of $68.09 million during the quarter, compared to analyst estimates of $66.01 million. During the same period in the prior year, the business posted ($0.37) earnings per share. Health Catalyst's revenue for the quarter was up 21.9% on a year-over-year basis. Research analysts forecast that Health Catalyst will post -1.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Health Catalyst news, insider Linda Llewelyn sold 1,860 shares of the firm's stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $15.87, for a total value of $29,518.20. Following the completion of the sale, the insider now directly owns 60,173 shares in the company, valued at $954,945.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Health Catalyst news, General Counsel Daniel H. Orenstein sold 2,838 shares of the firm's stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $14.85, for a total value of $42,144.30. Following the completion of the sale, the general counsel now directly owns 103,671 shares in the company, valued at $1,539,514.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Linda Llewelyn sold 1,860 shares of the firm's stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $15.87, for a total transaction of $29,518.20. Following the completion of the sale, the insider now owns 60,173 shares of the company's stock, valued at $954,945.51. The disclosure for this sale can be found here. Insiders sold 6,255 shares of company stock worth $93,877 over the last three months. Company insiders own 1.50% of the company's stock.

Receive HCAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Health Catalyst and its competitors with MarketBeat's FREE daily newsletter.

HCAT Stock News Headlines

One Stock Is All You Need 
Step-by-step guide to trading - and winning - in any market conditions with just ONE stock. Learn More. pixel
Health Catalyst (NASDAQ:HCAT) Reaches New 52-Week Low at $11.00
One Stock Is All You Need 
Step-by-step guide to trading - and winning - in any market conditions with just ONE stock. Learn More. pixel
Health Catalyst Earnings Preview
Short Volatility Alert: Health Catalyst, Inc.
What brokers are saying about Health Catalyst
Recap: Health Catalyst Q1 Earnings
Health Catalyst Reports First Quarter 2022 Results
See More Headlines
Receive HCAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Health Catalyst and its competitors with MarketBeat's FREE daily newsletter.

HCAT Company Calendar

Last Earnings
11/09/2021
Today
8/11/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Computer programming, data processing, & other computer related
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HCAT
Fax
N/A
Employees
1,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.69
High Stock Price Forecast
$48.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+108.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
12 Analysts

Profitability

Net Income
$-153,210,000.00
Pretax Margin
-58.90%

Debt

Sales & Book Value

Annual Sales
$241.93 million
Book Value
$8.57 per share

Miscellaneous

Free Float
53,902,000
Market Cap
$702.10 million
Optionable
Not Optionable
Beta
1.14














HCAT Stock - Frequently Asked Questions

Should I buy or sell Health Catalyst stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Health Catalyst in the last twelve months. There are currently 2 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HCAT shares.
View HCAT analyst ratings
or view top-rated stocks.

What is Health Catalyst's stock price forecast for 2022?

12 brokers have issued 12-month price targets for Health Catalyst's stock. Their HCAT share price forecasts range from $16.00 to $48.00. On average, they expect the company's share price to reach $26.69 in the next year. This suggests a possible upside of 106.0% from the stock's current price.
View analysts price targets for HCAT
or view top-rated stocks among Wall Street analysts.

How have HCAT shares performed in 2022?

Health Catalyst's stock was trading at $39.62 on January 1st, 2022. Since then, HCAT stock has decreased by 67.3% and is now trading at $12.96.
View the best growth stocks for 2022 here
.

When is Health Catalyst's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our HCAT earnings forecast
.

How were Health Catalyst's earnings last quarter?

Health Catalyst, Inc. (NASDAQ:HCAT) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.04. The company earned $61.74 million during the quarter, compared to the consensus estimate of $60.95 million. Health Catalyst had a negative trailing twelve-month return on equity of 18.31% and a negative net margin of 54.64%. During the same period last year, the company posted ($0.44) earnings per share.

What guidance has Health Catalyst issued on next quarter's earnings?

Health Catalyst updated its third quarter 2022 earnings guidance on Thursday, August, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $65.30 million-$68.30 million, compared to the consensus revenue estimate of $74.61 million.

What is Dan Burton's approval rating as Health Catalyst's CEO?

393 employees have rated Health Catalyst Chief Executive Officer Dan Burton on Glassdoor.com. Dan Burton has an approval rating of 99% among the company's employees. This puts Dan Burton in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Health Catalyst own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Health Catalyst investors own include NVIDIA (NVDA), Salesforce (CRM), Alteryx (AYX), Walt Disney (DIS), DocuSign (DOCU), Block (SQ), Slack Technologies (WORK), ServiceNow (NOW), Marvell Technology (MRVL) and PayPal (PYPL).

When did Health Catalyst IPO?

(HCAT) raised $129 million in an IPO on Thursday, July 25th 2019. The company issued 6,000,000 shares at $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and William Blair served as the underwriters for the IPO and Piper Jaffray, Evercore ISI, SVB Leerink and SunTrust Robinson Humphrey were co-managers.

What is Health Catalyst's stock symbol?

Health Catalyst trades on the NASDAQ under the ticker symbol "HCAT."

Who are Health Catalyst's major shareholders?

Health Catalyst's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include abrdn plc (2.62%), Victory Capital Management Inc. (1.61%), Pictet Asset Management SA (0.74%), Baillie Gifford & Co. (0.72%), Deutsche Bank AG (0.46%) and SG Americas Securities LLC (0.39%). Insiders that own company stock include Anita Pramoda, Bryan Richard Hinton, Bryan Truman Hunt, D Fraser Bullock, Dale Sanders, Daniel D Burton, Daniel H Orenstein, James Patrick Jr Nelli, Jason Alger, Linda Llewelyn, Paul Horstmeier and Timothy G Ferris.
View institutional ownership trends
.

How do I buy shares of Health Catalyst?

Shares of HCAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Health Catalyst's stock price today?

One share of HCAT stock can currently be purchased for approximately $12.96.

How much money does Health Catalyst make?

Health Catalyst (NASDAQ:HCAT) has a market capitalization of $709.17 million and generates $241.93 million in revenue each year. The company earns $-153,210,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis.

How many employees does Health Catalyst have?

The company employs 1,200 workers across the globe.

How can I contact Health Catalyst?

Health Catalyst's mailing address is 3165 MILLROCK DRIVE SUITE 400, SALT LAKE CITY UT, 84121. The official website for the company is www.healthcatalyst.com. The company can be reached via phone at (801) 708-6800 or via email at ir@healthcatalyst.com.

This page (NASDAQ:HCAT) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.